Health Care • Medical/Dental Instruments
$61.60 ▼ -1.59
(-2.52%)
MKT CAP: $199.2M • VOL: 43.1K
52W L $29 52W H $77
PDEX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $66.6M | $53.8M | $46.1M |
| YoY Revenue Growth % | +23.7% | +16.8% | — |
| Gross Profit | $19.5M | $14.6M | — |
| Gross Margin % | 29.3% | 27.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $10.7M | $7.2M | $5.8M |
| Operating Margin % | 16.1% | 13.3% | 12.5% |
| Net Income (GAAP) | $9.0M | $2.1M | $7.1M |
| EBITDA (Normalized) | $11.7M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.7M | $6.2M | $5.5M |
| Capital Expenditures (CapEx) | $1.2M | — | — |
| Free Cash Flow (FCF) | -$2.9M | $6.2M | $5.5M |
| FCF Margin % | -4.4% | 11.6% | 11.9% |
| Return on Invested Capital (ROIC %) | 23.2% | 17.8% | — |
| Cash & Short-Term Equivalents | $5.3M | $66.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $41.6M | $31.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PDEX.